MedTrace Logo

Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.

NCT00714285 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2018-06-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and immunogenicity of GSK influenza vaccine candidate compared to a licensed trivalent influenza vaccine in adults.

Conditions

Interventions

BIOLOGICAL

GSK Biologicals' quadrivalent influenza vaccine

Single intramuscular dose on Day 0.

BIOLOGICAL

GSK Biologicals' trivalent influenza vaccine

Single intramuscular dose on Day 0.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-14
Primary Completion
2009-01-28
Completion
2009-01-28

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00714285 on ClinicalTrials.gov